Analyst Research

Report Title Price
Trading Report for (SNY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
$58.00
Buy
ValuEngine Detailed Valuation Report for SNY
Provider: ValuEngine, Inc.
$127.00
Buy
Sanofi ADS
Provider: S&P Capital IQ – STARS Reports
$115.00
Buy
The Investment Rate - a measure of investment demand.
Provider: Stock Traders Daily
$495.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Oxford Biomedica PLC and Sanofi SA Report Positive Results in Eye Studies-PRNewswire


Wednesday, 8 Aug 2012 07:22am EDT 

PRNewswire reported that Oxford Biomedica PLC and Sanofi SA announced a positive interim review of the RetinoStat Phase I study in neovascular wet age-related macular degeneration and the StarGen Phase I/IIa study in Stargardt disease by the Data Safety Monitoring Board. RetinoStat and StarGen were designed and developed by Oxford Bio using its proprietary LentiVector gene delivery technology. 

Latest Developments for Sanofi SA

Latest Key Developments in Pharmaceuticals

Company Quote

Sanofi SA
(SNY)
54.74
0.18 +0.33%
24 May 2013